Thyroid Cancer With Autocrine Sialyl-fibronectin Depletion Has a Poor Prognosis due to EMT Progression.

Autor:	Miyake R; Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan., Takeyama H; Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan; takeyama@jikei.ac.jp., Manome Y; Institute of DNA Sciences, Yokohama, Japan., Koyama M; Department of Digestive Surgery, Jikei University School of Medicine, Tokyo, Japan., Tabei I; Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan., Shioya H; Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan., Kazama T; Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan., Nogi H; Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2024 Oct; Vol. 44 (10), pp. 4561-4568.
DOI:	10.21873/anticanres.17285
Abstrakt:	Background/aim: Elevated blood fibronectin (FN) levels have been observed in various cancers; however, their significance remains controversial. Herein, we measured the levels of sialyl-fibronectin (S-FN), a type of FN secreted by tumor cells, and investigated whether blood S-FN secretion is associated with recurrent metastasis and epithelial-mesenchymal transition (EMT). Patients and Methods: An ELISA system recognizing S-FN was constructed, and the amount of S-FN in blood samples from 63 patients with thyroid carcinoma was measured. The relationship between S-FN secretion and clinical prognosis was also examined. Vimentin immunostaining was performed to identify the mesenchymal status of the cells during EMT. Results: After 12 years of observation, 17/63 patients had recurrent metastases, including nine cases of lymph node recurrence (LNR) and eight cases of remote metastasis (RM). LNR occurred in 7/39 (17.9%) of S-FN-negative cases, where 4/7 (57.1%) had two or more repeat recurrences. In S-FN-positive cases, LNR was observed in 2/24 cases (8.3%), and no repeat recurrence was observed. For RM, 6/39 (15.4%) patients were S-FN-negative, of which 5/6 (83.3%) had progressive disease even during treatment at metastasis. Of the S-FN-positive cases, RM was observed in 2/24 (8.3%) patients; progressive disease was observed in 1/2 (50.0%) patients. In 9/11 S-FN-negative recurrent metastasis cases (81.8%) and 2/4 S-FN-positive cases (50.0%), many vimentin-positive, FN-secreting cells were found in the interstitial tissue around the tumor. Conclusion: S-FN-negative thyroid cancer has a poor prognosis because of the progression of EMT associated with increased paracrine FN levels in the stroma. (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu